IONS — Ionis Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00- $6.07bn
- $5.01bn
- $787.65m
- 66
- 11
- 70
- 47
Annual income statement for Ionis Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
R2019 December 31st | R2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 1,123 | 729 | 810 | 587 | 788 |
| Cost of Revenue | |||||
| Gross Profit | 1,118 | 717 | 800 | 573 | 779 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 823 | 901 | 849 | 998 | 1,128 |
| Operating Profit | 300 | -172 | -38.8 | -410 | -340 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 339 | -135 | -29.1 | -258 | -334 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 287 | -480 | -28.6 | -270 | -366 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | 278 | -444 | -28.6 | -270 | -366 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 278 | -444 | -28.6 | -270 | -366 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 2.18 | -3.04 | -0.053 | -2.59 | -2.62 |